Glaukos Co. (NYSE:GKOS) Shares Sold by Cynosure Group LLC

Cynosure Group LLC cut its holdings in shares of Glaukos Co. (NYSE:GKOS) by 29.6% in the 4th quarter, Holdings Channel reports. The fund owned 2,010 shares of the medical instruments supplier’s stock after selling 844 shares during the period. Cynosure Group LLC’s holdings in Glaukos were worth $301,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets grew its stake in Glaukos by 186.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier’s stock valued at $1,788,000 after purchasing an additional 8,942 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new position in shares of Glaukos during the 4th quarter valued at approximately $3,679,000. State Street Corp grew its position in shares of Glaukos by 5.3% during the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after buying an additional 98,109 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Glaukos in the third quarter worth $258,000. Finally, Rhumbline Advisers raised its holdings in Glaukos by 0.3% in the fourth quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier’s stock valued at $21,260,000 after acquiring an additional 403 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GKOS. Stifel Nicolaus raised their price objective on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. Needham & Company LLC boosted their price objective on Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a report on Friday, February 21st. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 target price (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. UBS Group started coverage on Glaukos in a report on Friday, December 6th. They issued a “buy” rating and a $182.00 price target for the company. Finally, Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $163.25.

Insider Transactions at Glaukos

In related news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares of the company’s stock, valued at $5,708,568.04. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

Shares of GKOS opened at $100.07 on Thursday. The firm has a fifty day moving average of $126.91 and a 200-day moving average of $135.14. The company has a market cap of $5.66 billion, a price-to-earnings ratio of -34.87 and a beta of 0.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 1 year low of $89.94 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. As a group, equities analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.